alefacept 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
lymphocyte function-associated antigen 3 receptors	5088	222535-22-0

Description:

Molecule	Description
Synonyms: alefacept BG9712 LFA3TIP BG9273 amevive	A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

alefacept
BG9712
LFA3TIP
BG9273
amevive

A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 30, 2003	FDA	ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Skin haemorrhage	236.42	197.46	59	2470	10035	63476458
Neurologic neglect syndrome	232.86	197.46	46	2483	2675	63483818
Carotid artery thrombosis	231.64	197.46	46	2483	2748	63483745
Adjustment disorder	213.95	197.46	44	2485	3134	63483359
Respiratory tract congestion	203.14	197.46	59	2470	17773	63468720
Sinus congestion	202.20	197.46	59	2470	18064	63468429
Sneezing	201.90	197.46	59	2470	18159	63468334
Personality disorder	198.08	197.46	46	2483	5765	63480728

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Skin haemorrhage	235.25	208.86	58	2446	11923	79729961
Neurologic neglect syndrome	234.52	208.86	45	2459	2862	79739022
Carotid artery thrombosis	232.32	208.86	45	2459	3008	79738876
Sneezing	211.27	208.86	59	2445	19624	79722260

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AA15	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants
FDA CS	M0018640	Recombinant Fusion Proteins
FDA CS	M0028142	Immunoconjugates
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D007155	Immunologic Factors
FDA MoA	N0000175857	CD2-directed Antibody Interactions
FDA EPC	N0000175859	CD2-directed LFA-3/Fc Fusion Protein

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Plaque psoriasis	indication	200965009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
T-cell surface antigen CD2	Surface antigen	P06729	CD2_HUMAN	INHIBITOR				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
ELK3V90G6C	UNII
D02800	KEGG_DRUG
4021373	VANDF
C0962603	UMLSCUI
CHEMBL1201571	ChEMBL_ID
DB00092	DRUGBANK_ID
D000077944	MESH_DESCRIPTOR_UI
8059	INN_ID
6787	IUPHAR_LIGAND_ID
299635	RXNORM
17114	MMSL
46117	MMSL
d04843	MMSL
009880	NDDF
398691006	SNOMEDCT_US
398857009	SNOMEDCT_US

Pharmaceutical products:

None